TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+10.67%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$735M
AUM Growth
–
Cap. Flow
+$735M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
55.66%
Holding
60
New
60
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Gilead Sciences
GILD
|
$77.1M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$62.9M |
| 3 |
CELG
Celgene Corp
CELG
|
$59.6M |
| 4 |
Biogen
BIIB
|
$41.3M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$36.3M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 84.4% |
| 2 | Financials | 1.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Madrigal Pharmaceuticals
MDGL
$9.7B
| $1.88M | 0.26% |
+376,750
| New | +$1.88M |
|
|
DNDN
52
DELISTED
DENDREON CORPORATION
DNDN
| $1.55M | 0.21% |
+376,728
| New | +$1.55M |
|
|
CERE
53
DELISTED
CERES, INC. COMMON STOCK NEW
CERE
| $1.3M | 0.18% |
+416,481
| New | +$1.3M |
|
54
Achieve Life Sciences
ACHV
$146M
| $1.11M | 0.15% |
+113,100
| New | +$1.11M |
|
55
MEI Pharma
MEIP
$149M
| $1.06M | 0.14% |
+148,820
| New | +$1.06M |
|
56
Supernus Pharmaceuticals
SUPN
$2.52B
| $905K | 0.12% |
+140,800
| New | +$905K |
|
|
ECYT
57
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $790K | 0.11% |
+60,200
| New | +$790K |
|
|
ICAD
58
DELISTED
iCAD Inc
ICAD
| $531K | 0.07% |
+88,527
| New | +$531K |
|
|
CRTX
59
DELISTED
CORNERSTONE THERAPEUTICS INC
CRTX
| $529K | 0.07% |
+66,112
| New | +$529K |
|
|
GCVRZ
60
DELISTED
Sanofi Contingent Value Rights
GCVRZ
| $200K | 0.03% |
+103,665
| New | +$200K |
|